CAJ | 학술논문

目的:对恩度(血管内皮抑素)联合TP方案化疗治疗晚期非小细胞肺癌的近期疗效、不良反应进行评价.方法:选择经病理组织学或细胞学确诊的晚期非小细胞肺癌患者68例,随机分为恩度联合TP方案化疗组37例和单纯TP方案化疗组31例.恩度联合TP方案化疗组给予TXT65mg/m~2,分2次给药(第2、9天),顺铂75 mg/m~2,分4次给药(第1、2、3、4天),恩度15mg,连用14天,休息1周.单纯化疗组仅给予常规TP方案化疗.21夭为1周期,两周期治疗结束后参照WHO评价标准,对其近期疗效、不良反应进行评价.结果:联合化疗组有效率为56.8%,单纯化疗组为29.7%,两组比较差异有显著性意义(X~2=4.08,P<0.05).两组主要不良反应为骨髓抑制,消化道反应和脱发.恩度联合化疗组发生率分别为59.4%、39.1%、81.1%,单纯化疗组发生率分别为64.5%、38.7%、83.9%.不良作用主要与化疗药物有关,两组的发生率无显著性差异(P>0.05).结论:恩度联合TP方案化疗治疗晚期非小细胞肺癌安全,且能提高化疗疗效,值得临床推广使用和进一步深入观察.
목적:대은도(혈관내피억소)연합TP방안화료치료만기비소세포폐암적근기료효、불량반응진행평개.방법:선택경병리조직학혹세포학학진적만기비소세포폐암환자68례,수궤분위은도연합TP방안화료조37례화단순TP방안화료조31례.은도연합TP방안화료조급여TXT65mg/m~2,분2차급약(제2、9천),순박75 mg/m~2,분4차급약(제1、2、3、4천),은도15mg,련용14천,휴식1주.단순화료조부급여상규TP방안화료.21요위1주기,량주기치료결속후삼조WHO평개표준,대기근기료효、불량반응진행평개.결과:연합화료조유효솔위56.8%,단순화료조위29.7%,량조비교차이유현저성의의(X~2=4.08,P<0.05).량조주요불량반응위골수억제,소화도반응화탈발.은도연합화료조발생솔분별위59.4%、39.1%、81.1%,단순화료조발생솔분별위64.5%、38.7%、83.9%.불량작용주요여화료약물유관,량조적발생솔무현저성차이(P>0.05).결론:은도연합TP방안화료치료만기비소세포폐암안전,차능제고화료료효,치득림상추엄사용화진일보심입관찰.
Objective: To evaluate the efficacy and toxic reactions of Endostar combined with TP chemo-therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Methods: A total of 68 cases of advanced stage NSCLC confirmed by pathohistology or cytology were randomly divided into two treate-ment groups: the Endostar combined with TP chemotherapy group (37 cases) and the simple TP chemothera-py group (31 cases). Patients in the Endostar combined with TP chemotherapy group were treated with TXT 65mg/m~2 on d2 and d9, DDP 75 mg/m~2, d1-4; and endostar 15g, d1-14. Patients in the simple chemotherapy group were treated with TXT and DDP. After 2 weeks, we estimated the recent curative effect and toxic reac-tions according to WHO standard. Results: The total response rates in the two groups were 56.8% and 29.7%, respectively, with a significant difference (X~2=4.08, P<0.05). The main toxic reactions were bone marrow sup-pression, gastrointestinal reactions and hair loss. And the incidences of the above three toxic reactions were 59.4%, 39.1%, and 81.1% in the endostar combined with chemotherapy group and 64.5%, 38.7%, and 83.9% in the simple chemothotherapy group. The toxic reactions were mainly related to chemotherapeutics and were not significantly different between the two groups (P>0.05). Conclusion: Endostar combined with chemothera-py is a safe method to treat advanced stage NSCLC. Endostar can improve the curative effect of chemothera-py. This method deserves to be clinically practiced and observed further.